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Abstract 
Background: Appropriate diagnosis and treatment are essential for reducing malaria mortality. A cross-sectional 
outpatient health facility (HF) survey was conducted in southern Malawi from January to March 2015 to determine 
appropriate malaria testing and treatment practices four years after implementation of a policy requiring diagnostic 
confirmation before treatment.
Methods: Enrolled patients were interviewed, examined and had their health booklet reviewed. Health workers 
(HWs) were asked about training, supervision and access to the 2013 national malaria treatment guidelines. HFs were 
assessed for malaria diagnostic and treatment capacity. Weighted descriptive analyses and logistic regression of 
patient, HW and HF characteristics related to testing and treatment were performed.
Results: An evaluation of 105 HFs, and interviews of 150 HWs and 2342 patients was completed. Of 1427 suspect 
uncomplicated malaria patients seen at HFs with testing available, 1072 (75.7%) were tested, and 547 (53.2%) tested 
positive. Testing was more likely if patients spontaneously reported fever (odds ratio (OR) 2.6; 95% confidence interval 
(CI) 1.7–4.0), headache (OR 1.5; 95% CI 1.1–2.1) or vomiting (OR 2.0; 95% CI 1.0–4.0) to HWs and less likely if they 
reported skin problems (OR 0.4; 95% CI 0.2–0.6). Altogether, 511 (92.7%) confirmed cases and 98 (60.3%) of 178 pre-
sumed uncomplicated malaria patients (at HFs without testing) were appropriately treated, while 500 (96.6%) of 525 
patients with negative tests did not receive anti-malarials. Only eight (5.7%) suspect severe malaria patients received 
appropriate pre-referral treatment. Appropriate treatment was more likely for presumed uncomplicated malaria 
patients (at HFs without testing) with elevated temperature (OR 1.5/1 °C increase; 95% CI 1.1–1.9), who reported fever 
to HWs (OR 5.7; 95% CI 1.9–17.6), were seen by HWs with additional supervision visits in the previous 6 months (OR 
1.2/additional visit; 95% CI 1.0–1.4), or were seen by older HWs (OR 1.1/year of age; 95% CI 1.0–1.1).
Conclusions: Correct testing and treatment practices were reasonably good for uncomplicated malaria when testing 
was available. Pre-referral treatment for suspect severe malaria was unacceptably rare. Encouraging HWs to elicit and 
appropriately respond to patient symptoms may improve practices.
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Background
Approximately 214 million malaria cases and 438,000 
malaria deaths occurred worldwide in 2015 [1]. Use 
of artemisinin-based combination therapy (ACT) for 
uncomplicated malaria and parenteral quinine or arte-
misinins for severe malaria is highly effective in prevent-
ing malaria deaths when prompt diagnosis and timely 
treatment is initiated [2]. Since 2010, to better target anti-
malarial treatment and more appropriately manage non-
malarial fevers, the World Health Organization (WHO) 
has recommended diagnostic testing of all suspect 
malaria patients before initiating treatment [3]. Nearly 
all malaria-endemic countries have updated their malaria 
case-management policies to reflect these recommenda-
tions and most have made rapid diagnostic tests (RDTs) 
for malaria widely available at health facilities (HFs). 
However, gaps in health worker (HW) practices based 
on current recommendations have been reported in a 
variety of settings. A recent systematic review and meta-
analysis of 14 studies, 11 of which were conducted after 
2010, reported that administration of appropriate malaria 
treatment based on RDT results ranged from 39.7% in 
Zambia to 99.9% in Zanzibar [4].
The entire population of Malawi (18 million people) is 
at risk for malaria [5]. An estimated six million cases of 
malaria occur annually, accounting for 29% of outpatient 
visits across all ages and 40% of all hospitalizations among 
children under five years of age. Presumptive treatment 
of malaria among febrile patients was the norm until 
2011, when the Malawi National Malaria Control Pro-
gramme (NMCP) adopted the WHO recommendation 
to diagnostically confirm malaria cases before initiating 
treatment [6]. To support this initiative, the Malawi Min-
istry of Health (MoH) made RDTs widely available in HFs 
across the country later that year. Prompt and effective 
case management of malaria patients is one of the key 
malaria control efforts in Malawi [6], but previous studies 
have indicated shortcomings in correct treatment. Prior 
to the widespread availability of RDTs in Malawi, a 2011 
national HF survey reported that only 67% of patients 
with uncomplicated malaria received a prescription for 
the first-line ACT, artemether-lumefantrine (AL) [7]. In 
addition, 31% of patients without malaria received AL 
[7], and 22% of patients with a negative microscopy test 
at the HF were prescribed AL [8].
To promote HWs’ knowledge and adherence to 
national malaria treatment guidelines, the NMCP has 
utilized a multipronged approach, including provi-
sion of in-service and refresher training, distribution of 
printed copies of the guidelines and periodic supportive 
supervision. In 2014 and 2015, HWs in Malawi received 
refresher training on malaria case management based on 
the latest malaria treatment guidelines released in July 
2013. In addition to recommending testing of suspect 
uncomplicated malaria patients before administration of 
ACT, the guidelines emphasized immediate administra-
tion of rectal (primarily at community level) or parenteral 
artesunate or parenteral quinine as pre-referral, life-sav-
ing treatment for severe malaria at outpatient HFs [9].
The objective of this survey was to assess the quality of 
malaria case management at outpatient HFs, based on 
HW adherence to Malawi’s latest national malaria treat-
ment guidelines, almost 4  years after roll-out of RDTs 
and several months after malaria case-management 
refresher training.
In addition, an evaluation of HF, HW and patient-level 
attributes and their associations with appropriate testing 
and treatment of suspect uncomplicated malaria patients 
was performed to identify opportunities to improve case-
management quality.
Methods
Study design and data collection
This cross-sectional study was conducted in southern 
Malawi, a region with malaria prevalence estimates 
among children under 5 years old of 30% [6] and among 
5 to 21  years olds of 60% [10]. The survey collected 
baseline data for a cluster-randomized, controlled trial 
to evaluate the effectiveness of mobile phone text-mes-
sage reminders to HWs to improve the case manage-
ment of fever, pneumonia and diarrhoea. Seven of 13 
districts in the region were selected if their HWs had 
received malaria case-management refresher training 
in 2014. The seven districts were: Chikwawa, Nsanje, 
Thyolo, Blantyre, Chiradzulu, Mulanje, and Phalombe. 
The majority (89%) of HFs in Malawi are operated by 
either the MoH or Christian Health Association of 
Malawi (CHAM) [11], and all such HFs follow the 
national malaria treatment guidelines. MoH facilities 
provide free services, while CHAM facilities require 
a small co-pay. The survey was performed to pro-
vide baseline data for a cluster-randomized controlled 
trial of text message reminders to HWs to assess their 
impact on HW adherence to national malaria treat-
ment guidelines.
Only health centres and district, community or rural 
hospitals operated by the MoH or CHAM with a func-
tional outpatient department (OPD), and road acces-
sibility were included. The targeted sample size was 105 
facilities based on sample sizes needed for the larger text 
message trial. From 22 January to 5 March, 2015, during 
high malaria transmission season, survey teams evalu-
ated the 105 participating facilities and assessed HW 
adherence to the latest national malaria treatment guide-
lines. During the survey, six facilities in Chikwawa and 
Nsanje could not be accessed due to poor road conditions 
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during the rainy season and were, therefore, replaced by 
six facilities from Phalombe district.
Data were collected by four survey teams via ques-
tionnaires in CommCare version 2.24.0 (Dimagi, Inc) 
using ASUS Nexus 7 Android tablets (Taipei, Taiwan). 
Each team visited one HF for a full day during the work-
ing week (Monday to Friday) and randomly selected 
one OPD (if the facility had more than one) and con-
ducted patient exit interviews, HW interviews and HF 
assessments.
All patients attending selected OPDs between 08:00 
and 16:00 h on the day of the survey comprised the sam-
pling frame. Patients were screened for eligibility after 
selection using systematic sampling with a skip interval 
determined by patient volume 1 week prior, calculated to 
yield approximately 20 patients/HF day. The first patient 
within the skip interval was randomly selected. If a 
selected patient did not meet eligibility criteria, investi-
gators approached the next patient using the pre-deter-
mined skip interval. Selected patients were enrolled if 
they met eligibility criteria which were that it was their 
first visit to the facility for the current illness and they or 
their caregivers provided written informed consent. All 
HWs performing clinical consultations in the selected 
OPDs were eligible for interviews and were assigned 
unique identification numbers. Enrolled patients were 
given study cards on which HWs placed their identifica-
tion numbers and recorded patient diagnoses during the 
clinical encounter.
Patient exit interviews were completed at the end of the 
patient’s visit. Surveyors asked patients (or their caregiv-
ers) about current malaria-related symptoms spontane-
ously reported to the HW, whether HWs had specifically 
asked about the presence/history of fever, any anti-malar-
ials they had taken at home, their clinical encounter with 
the HW, any laboratory tests done, and any anti-malarial 
medications administered, dispensed or prescribed at the 
HF. If ACT were dispensed to the patients, their knowl-
edge regarding the number of ACT tablets to take for 
each dose, the number of doses to take per day, and the 
number of days to take the entire ACT course was evalu-
ated through open-ended questions. Additional patient 
information was obtained from the patient’s personal 
health booklet, the individual health record on which 
their clinical encounter is typically documented at the 
HF. Surveyors then conducted a brief physical examina-
tion, including measurement of axillary temperature and 
preparation of thick and thin blood smears for subse-
quent reference laboratory evaluation, on every patient 
interviewed. If a patient reported fever, or if the surveyor-
measured temperature was  ≥37.5  °C and the patient 
had not been prescribed first-line anti-malarials by the 
HW, a malaria RDT (SD Bioline malaria Pf®, Standard 
Diagnostics, Inc, Giheng-ku, Republic of Korea) was per-
formed by the survey team and, if positive, the first-line 
anti-malarial was dispensed to the patient.
At the end of the day, all HWs conducting clinical con-
sultations in the selected OPD on the day of the survey 
were interviewed. They were asked about their professional 
training, training in malaria case management, supervi-
sion, years of clinical experience, and if they had access to 
a copy of the latest malaria treatment guidelines dated July 
2013. A visual confirmation of the available malaria treat-
ment guidelines was made. Finally, HF assessments were 
completed for each site. Survey teams asked the facility in-
charge about staffing and equipment, and visually verified 
the presence of malaria RDTs, drug stocks, drinking water 
for directly observed treatment, and other equipment 
related to malaria case management on the day of the study.
Malaria case definitions
Malaria case definitions were based on the 2013 Malawi 
national treatment guidelines [9] (Table  1). Confirmed 
malaria was defined as all suspect uncomplicated malaria 
patients who received malaria testing at the HF (as part 
of routine case management) by either microscopy or 
RDT and tested positive prior to interview/enrolment in 
the study. Presumed malaria was defined as all suspect 
uncomplicated malaria patients who attended HFs with 
no malaria diagnostic services available on the day of the 
survey. Non-malaria was defined as all suspect uncom-
plicated malaria patients who attended HFs with malaria 
diagnostic services and tested negative by either micros-
copy or RDT at the health facility, prior to interview/
enrolment in the study.
Definition of outcomes
Outcomes were based on Malawi’s 2013 malaria treat-
ment guidelines. Appropriate testing was defined as: 
(1) the patient presented with symptoms of suspect 
uncomplicated malaria (see Table 1); (2) at a facility with 
malaria-testing services available the day of the sur-
vey; and, (3) the patient was tested for malaria by either 
RDT or microscopy. Appropriate treatment was defined 
according to the following categories for suspect uncom-
plicated malaria patients: (1) attended HFs with malaria 
tests available, tested negative for malaria and did not 
receive an ACT; or (2) tested positive and received an 
ACT; or, (3) attended HFs without malaria tests available 
and received an ACT (presumptively treated for malaria). 
Patients were considered to have received an ACT if it 
had been prescribed, administered or dispensed at the 
HF prior to interview/enrollment in the study (to distin-
guish from treatments the study team initiated). Suspect 
severe malaria patients (see Table  1) were considered 
to have received appropriate treatment if they received 
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intramuscular (IM) artesunate or IM quinine. In-patient 
intravenous treatment with artesunate at a larger hospital 
level should then follow.
Statistical analyses
Data were analysed in SAS 9.3 (SAS Institute, Inc, Cary, 
NC, USA) and included weighted descriptive analyses of 
patient-level attributes adjusting for non-response and 
the sampling scheme, including clustering at the HF level. 
In addition unweighted descriptive analyses of HW and 
HF attributes were performed.
To explore factors associated with appropriate test-
ing and treatment, univariable and multivariable logistic 
regression modelling was conducted for each outcome, 
using the SURVEYLOGISTIC procedure, which accounts 
for the weights and complex survey design, including 
clustering at the HF level [12, 13]. For the multivariable 
analysis, plausible effect modifiers were explored using 
12 interaction terms and included in the model if sig-
nificant. Variables were explored as interaction terms if 
there was plausibility for interaction or if they had been 
reported as such in peer-reviewed literature. Factors were 
included in the multivariable model if they had a p < 0.1 
in the univariable analysis. The base multivariable model 
was checked for collinearity and confounding. Covariates 
were retained in the model as confounders if the odds 
ratio (OR) of any variable in the base model changed 
by at least 20%, unless the original variables in the base 
model had p  >  0.05 and remained non-significant after 
adding potential confounders.
Factors associated with appropriate testing were exam-
ined for all suspect uncomplicated malaria patients 
attending HFs able to test for malaria on the day of the 
survey visit. However, analysis of factors related to appro-
priate treatment was limited to presumed uncomplicated 
malaria patients given the lack of variability (consist-
ently high performance) for patients with positive diag-
nostic tests (confirmed malaria) and negative tests (not 
malaria). Considering the relatively small sample size of 
presumed malaria patients (n  =  178), the most stable 
model with the lowest condition index [14] was selected 




The geographic distribution of the 105 facilities surveyed 
across the seven study districts is provided in Fig. 1. Alto-
gether 153 HWs providing outpatient consultations at 
participating HFs during the survey period were enrolled, 
and interviews were completed with 150. A total of 2877 
patients waiting in OPDs were screened and 2645 were 
eligible. Of these, 2567 (97.1%) consented to participate 
in the study and 2354 (89.0%) completed exit interviews. 
Patients were not interviewed if they were found to be 
too ill to complete the exit interview or were missed 
by the study team after they completed their clinical 
encounters.
Health facility characteristics
Of the 105 surveyed HFs, 80% were operated by MoH 
(Table  2). The sample included 90 health centres, nine 
community hospitals and six district hospitals. Most 
HFs had functional malaria diagnostic services, primar-
ily RDTs (79%), and only 25% had microscopy. Test-
ing was usually available for the full day of the survey 
[94/105 facilities (90%)], but seven facilities did not have 
testing available the day of the survey and an additional 
four facilities had testing available for part of the survey 
day. Nearly half (48%) of HFs had a copy of 2013 national 
malaria treatment guidelines or other MoH reference 
material with malaria treatment content, for example, a 
primary care handbook.
Ninety-six (91%) HFs had either the first-line (AL) or 
second-line (artesunate-amodiaquine (ASAQ)) ACT 
available for the full day of the survey. The majority of 
HFs (91%) had at least one AL formulation available, 
with individual dose-pack availability ranging from 73% 
for both AL 2 × 6 and AL 4 × 6 dose-packs, 79% for AL 
3  ×  6, to 84% for AL 1  ×  6 dose-packs. ASAQ was in 
stock at 31% of HFs. Quinine tablets were in stock at 35%, 
parenteral artesunate at 84% and parenteral quinine at 
89% of HFs. Nearly all HFs (98%) had at least one inject-
able pre-referral treatment in stock.
Table 1 Malaria definitions
a History of fever was defined as: (1) Patient mentioned that their current illness 
involved a fever when asked by surveyor during the exit interview. (2) Patient 
spontaneously reported fever to the HW. (3) Patient reported fever to the HW or 
surveyor when asked
1. Suspect uncomplicated malaria categories by age and pregnancy 
status
Children <5 years of age or pregnant women in the first trimester:
 History of fevera or measured axillary temperature ≥37.5 °C
Patients ≥5 years of age
 History of fevera or measured axillary temperature ≥37.5 °C AND at 
least one additional sign or symptom suggestive of malaria (i.e., 
chills, muscle or joint pain, headache, vomiting, diarrhoea, weakness, 
nausea, dizziness, fatigue or abdominal pain)
2. Suspect severe malaria
 Patients with any of the following: history of convulsions, lethargy, no 
urine output, jaundice, coca-cola-coloured urine, palmar pallor, or 
vomiting everything
 For patients <5 years of age, neck stiffness or unable to drink or breast-
feed were also included
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Health worker characteristics
Of 150 HWs performing outpatient consultations during 
the survey, 73% were male; median HW age was 29 years, 
with a median of four years of clinical experience (Table 3). 
Nearly half (47%) had a copy of the 2013 national malaria 
treatment guidelines, and 67% had received at least one 
supervision visit in the previous 6 months.
Patient characteristics
For the 2342 patients who completed the exit interview, 723 
(28%) were under 5 years old; among these younger patients, 
79% had suspect uncomplicated malaria and 6% had suspect 
severe malaria (Table  4). Overall, 73% of all study partici-
pants had suspect malaria, the majority of whom (95%) had 
suspect uncomplicated malaria. Of 1619 patients aged at 
Fig. 1 Map of southern Malawi showing 99 of 105 participating health facilities with GPS coordinates
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least 5 years, 67% had suspect uncomplicated malaria and 
2% had suspect severe malaria. In this study, 69% of sus-
pect malaria patients spontaneously reported fever to the 
HW (Table 4). When patients did not spontaneously report 
fever, HWs asked patients about it a little over half the time 
(52%). Other symptoms spontaneously reported to the HW 
included headache (33%), vomiting (17%) and skin problem 
(6% of suspect malaria patients).
Malaria testing and treatment practices among suspect 
malaria patients
Of 2096 patients who attended facilities with malaria 
testing services, 1427 (70%) had suspect uncomplicated 
malaria and therefore required parasitologic testing. Of 
those, 76% were tested, over half (53%) of whom tested 
positive (confirmed malaria). Although most confirmed 
malaria patients (93%) were appropriately treated, nearly 
Table 2 Summary characteristics of surveyed outpatient health facilities—Southern Malawi, 2015 (N = 105)
a An additional 4 facilities had testing availability for part of the day
n %
Operation of health facility
 Ministry of Health 84 80.0
 CHAM 21 20.0
Health facility type
 Health centre 90 85.7
 Community hospital 9 8.6
 District hospital 6 5.7
Diagnostic capacity
 Microscopy service functional for full day of survey 26 24.8
 RDTs in stock for full day of survey 83 79.1
 Either microscopy or RDT functional for day of surveya 94 89.5
 Haemoglobin testing functional for full day 11 10.5
Infrastructure and equipment available on day of survey
 Clean drinking water 93 88.6
 Cups for administering oral medications available 69 65.7
 Functioning hanging or standing scale 98 90.5
 Functioning thermometer 69 65.7
Availability of 2013 malaria treatment guidelines on day of survey
 Copy of 2013 national or other reference material on malaria treatment guidelines 50 47.6
 Wall flowchart with 2013 malaria treatment guidelines 14 13.3
Anti-malarial drugs in stock for the full day on day of survey
A. First-line treatment for uncomplicated malaria in pregnant women (1st trimester) and children <5 kg
 Quinine tablets 37 35.2
B. First-line treatment for uncomplicated malaria in all other patients
 At least one artemether-lumefantrine (AL) formulation 96 91.4
 AL 1 × 6 dose-pack (regular or dispersible) 88 83.8
 AL 2 × 6 dose-pack (regular or dispersible) 77 73.3
 AL 3 × 6 dose-pack 83 79.1
 AL 4 × 6 dose-pack 77 73.3
C. Second-line treatment for uncomplicated malaria (treatment failure or when AL is contra-indicated)
 Artesunate-amodiaquine (co-formulated or co-blistered) 32 30.5
 Any first- or second-line anti-malarial treatment for uncomplicated malaria 98 93.3
D. Pre-referral treatment for severe malaria
 Any injectable pre-referral treatment (artesunate or quinine) 103 98.1
 Parenteral artesunate 88 83.8
 Parenteral quinine 94 89.5
 Artesunate suppositories 6 5.7
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5% received a non-recommended anti-malarial (quinine, 
sulfadoxine-pyrimethamine (SP), or AL for pregnant 
women in the first trimester), and 3% received no anti-
malarial. Of 525 patients with negative test results, 96% 
were not treated with any anti-malarial. Among the 29 
patients who received an anti-malarial, 25 received AL, two 
received quinine, and two received SP (none was pregnant).
Of 246 patients who attended facilities without malaria 
testing services, 75% had presumed uncomplicated malaria. 
The first- or second-line anti-malarial was prescribed, 
administered or dispensed to 60% of them, 3% received SP 
(none was pregnant), and 37% received no anti-malarial.
Of 90 suspect severe malaria patients, 53% had a sign 
of severe malaria documented in their record by the HW. 
However, only 6% of the 90 patients received appropri-
ate pre-referral treatment, 7% were immediately referred 
to the hospital or admitted, and only 2% received both 
pre-referral treatment and referral/admission, the rec-
ommended treatment for severe malaria according to 
the national malaria treatment guidelines. Most (60%) 
suspect severe malaria patients were given an oral 
anti-malarial, mainly AL; 35% did not receive any anti-
malarial. A summary of appropriate malaria treatment 
practices is provided in Fig.  2. In accordance with the 
guidelines, malaria testing was not considered as part of 
appropriate treatment for suspect severe malaria.
Dispensing and dosing practices and patient knowledge 
among uncomplicated malaria patients who had an ACT 
dispensed at the HF
Of 609 uncomplicated malaria patients who received an 
ACT (either AL or ASAQ), 534 (89%) had the drug dis-
pensed at the HF (Table  5); dosing was correct for 95%. 
Correct dosing was based on age and weight as stated 
in the guidelines. While 92% of uncomplicated malaria 
patients received an explanation from the HW regarding 
how to take the ACT at home, only 8% were told what to 
do in case of vomiting within 30 min of taking the drug.
Table 3 Summary characteristics of  health workers providing outpatient care at  surveyed health facilities—Southern 
Malawi, 2015 (N = 150a)
a Six of the 150 HWs did not see any enrolled patients but were interviewed by the survey teams
b Nurse category includes 20 nurse midwife technicians (3 years of formal training) and a Registered nurse (with a 4-year degree)
c In-service malaria case-management training refers to a formal, typically off-site multiday training on malaria diagnosis and treatment
d On-the-job training is an informal training provided to health workers at their place of employment by the facility in-charge, a co-worker, NGO staff, District Health 
Management Team or other Ministry of Health staff
e Assessment of health workers’ knowledge on malaria treatment practices involves any or all of the following: (1) direct in-office observation of patient consultations; 
(2) review of patients’ health passports for malaria laboratory results and prescriptions; (3) quizzing HWs on national anti-malarial treatment guidelines; (4) reviewing 
dosing schedule of prescribed malaria prescriptions with patients to evaluate their understanding
n %
Cadre of health worker caring for patients in sampled outpatient department
 Medical assistant (2 years of formal training plus 1 year internship) 100 66.7
 Clinical officer (3 years of formal training plus 1 year internship) 23 15.3
 Nurseb (at least 3 years of formal training) 21 14.0
 Patient attendant (no formal training) 4 2.7
 Pharmacy technician (2 years of formal training) 1 0.7
 Health surveillance assistant (6 weeks of formal training) 1 0.7
Training and guidelines
 Malaria case management (in-service)c training ≥2013 113 75.3
 Malaria case management (on-the-job)d training ≥2013 53 35.3
 Either in-service or on-the-job malaria case management training ≥2013 128 85.3
 Integrated management of childhood illness (IMCI) training within the last 5 years 27 18.0
 Has a copy of the latest malaria treatment guidelines (dated ≥2013) 70 46.7
Supervision
 Received any supervision in the past 6 months 101 67.3
 Received at least two supervisory visits in the past 6 months 67 44.7
 Supervision visits that included observation of patient consultations 55 36.7
 At least one supervisory visit with observation of patient consultations that involved assessing  
health workers’ knowledge and prescription practices of anti-malarial drugse
36 24.0
Other characteristics Median (IQR) Min–Max
 Age 29.0 (26.0, 36.0) 21–75
 Years of experience 4.0 (2.0, 7.0) 0–45
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Most patients with uncomplicated malaria (78%) 
demonstrated correct knowledge regarding AL dosing, 
including the amount of drug per dose, the number of 
doses per day and the total number of days to complete 
the full dose for patients who received AL (Table 5).
Factors associated with appropriate testing among suspect 
uncomplicated malaria patients
Fourteen patient-level, ten HW-level, six HF-level factors, 
and 12 interaction terms were tested for association with 
HW testing practices among suspect uncomplicated malaria 
patients in univariable logistic regression. None of the HW 
or HF factors was included in the multivariable logistic 
model model, as they had p > 0.1 in univariable analyses, but 
were tested for confounding. None of them was found to be 
confounders. All patient-level factors included in the mul-
tivariable model were statistically significant (Table 6). The 
model also included an interaction between a HW receiving 
at least one supervision visit in the previous 6 months and 
possession of a copy of the 2013 national malaria treatment 
guidelines. Of 1427 suspect uncomplicated malaria patients 
who should have been tested for malaria, those who spon-
taneously reported history of fever (OR 2.6; 95% CI 1.7–
4.0), headache (OR 1.5; 95% CI 1.1–2.2), and vomiting to 
Table 4 Characteristics and outcomes for patients who completed the exit interview—Southern Malawi, 2015
a First- or second-line AM refers to artemether-lumefantrine (AL) or artesunate-amodiaquine (ASAQ) for all except pregnant women in first trimester and children 
weighing <5 kg who get quinine. Numerator includes eight confirmed malaria patients who got both AL and intramuscular (IM) quinine and one confirmed malaria 
patient who got both AL and IM artesunate
b Oral quinine (n = 6), IM quinine (n = 3), AL to women in first trimester (n = 2), SP (n = 1)
c All given sulfadoxine-pyrimethamine (SP) none of whom was pregnant
d Three received IM artesunate, five received IM quinine
e 42 patients received only AL, one received both AL and SP, one received ASAQ and two received oral quinine
n/N Weighted percent (95% CI)
Demographics (years)
 <5 723/2342 28.3 (21.8, 34.8)
 ≥5 1619/2342 71.7 (65.2, 78.2)
Suspect malaria classification
 Suspect malaria cases (both uncomplicated and severe) 1695/2342 73.4 (70.2, 76.6)
 Suspect uncomplicated malaria 1605/1695 95.4 (94.2, 96.6)
 Suspect severe malaria 90/1695 4.6 (3.4, 5.8)
Symptoms spontaneously reported to HW by suspect malaria patients
 Fever 1146/1695 68.5 (64.0, 73.0)
 When patient did not spontaneously report fever, HW asked about fever 295/549 51.6 (46.0, 57.2)
 Headache 553/1695 33.4 (28.6, 38.2)
 Vomiting 284/1695 16.9 (14.3, 19.5)
 Skin problem 99/1695 5.5 (3.9, 6.9)
Testing for suspect uncomplicated malaria patients who attended HFs with diagnostic tests
 Tested by either microscopy or RDT 1072/1427 75.7 (68.9, 82.5)
 Positive RDT or microscopy 547/1072 53.2 (46.0, 60.4)
Medications administered, prescribed or dispensed to confirmed uncomplicated malaria patients
 Treated with first- or second-line antimalarial (AM)a 511/547 92.7 (85.4, 99.9)
 Treated with other anti-malarialb 12/547 4.7 (0.0, 11.9)
 No anti-malarial 24/547 2.6 (1.2, 4.0)
Medications administered, prescribed or dispensed to presumed uncomplicated malaria patients
 Treated with first- or second-line AMa 98/178 60.3 (45.1, 75.5)
 Treated with other anti-malarialc 5/178 2.8 (0.0, 8.3)
 No anti-malarial 75/178 36.8 (22.8, 50.8)
Suspect severe malaria
 Received recommended pre-referral anti-malariald 8/90 5.7 (0.3, 11.0)
 Referred or told to get in-patient admission right away 11/90 6.9 (1.9, 11.9)
 Received pre-referral anti-malarial plus immediate referral/admission 3/90 1.6 (0.0, 3.6)
 Treated with other anti-malariale 46/90 59.6 (46.4, 72.8)
 No anti-malarial 36/90 34.7 (22.4, 47.0)
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the HW had higher odds of getting tested (OR 2.0; 95% CI 
1.0–4.0). Conversely, patients who spontaneously reported 
a skin problem to the HW were 60% less likely to get tested 
(OR 0.4; 95% CI 0.2–0.6).
Interestingly, the effect of having access to a copy of 
the 2013 national malaria treatment guidelines on testing 
differed depending on whether or not the HW had had 
a supervision visit in the previous 6  months (Table  6). 
For HWs that were not supervised, the odds of test-
ing was higher among those who had guidelines com-
pared to those who did not. Only 57% of patients seen 
by HWs who were neither supervised in the previous 
6 months nor possessed a copy of the guidelines were 
tested, compared to 76, 79 and 87% of patients seen by 
HWs with both supervision and guidelines, supervision 
but not guidelines, and guidelines but not supervision, 
respectively.
Of the 289 suspect uncomplicated malaria patients 
seen by HWs with neither supervision nor guidelines, 46 
were seen by HWs whose colleagues at the facility had 
received some supervision or guidelines and 76% of them 
were tested for malaria (same testing rate for the rest of 
the study population). The other 243 patients were seen 
by HWs who either: (1) worked alone and had received 
neither supervision nor possessed a copy of the guide-
lines; or, (2) worked with other HWs who like themselves, 
had received neither. Only 52% of patients seen by this 
latter category of HWs were tested. In total, there were 
18 HWs located at 16 HFs in this category. There were 
no observed differences between these 18 HWs and other 
HWs in terms of age, years of clinical experience, type 
of formal training, malaria-related training received, or 
the type of HF where they worked. Furthermore, there 
were no statistically significant differences in distances 
of these HFs where HWs had neither recent supervision 
nor guidelines to their respective district hospitals than 
between the other facilities and the district hospitals.
Factors associated with appropriate treatment 
among presumed uncomplicated malaria patients
The same patient-, HW- and HF-level factors and 12 
interaction terms were evaluated for an association 
with correct treatment among presumed uncomplicated 
malaria patients. Patients who spontaneously reported 
history of fever to the HW had a nearly six-fold higher 
odds of appropriate treatment (OR 5.7; 95% CI 1.9–17.6) 
(Table 7). The odds of appropriate malaria treatment were 
also increased as measured temperature increased (for 
each degree rise in patient temperature OR 1.5; 95% CI 
1.1–1.9), HW age increased (for each additional year in 
HW age OR 1.1; 95% CI 1.0–1.1), and number of supervi-
sion visits in the previous 6 months to the HW increased 
(OR 1.2; 95% CI 1.0–1.4). A patient’s spontaneous com-
plaint of headache to the HW was a confounder and was 
therefore included in the final model. Notably, for both 
the models of correct testing and treatment, there was 
no significant association with HWs who had received 
the latest training on malaria case management, whether 
they had a copy of the latest malaria testing guidelines, or 
their length of clinical experience.
Discussion
Malaria case-management services, including both diagnos-
tics and treatment, were widely available in outpatient HFs 
in southern Malawi, representing tremendous progress over 




















Fig. 2 Summary of appropriate malaria treatment practices among suspect malaria patients
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before RDTs became widely available, found that only 24% of 
HFs across the country had functional microscopy services 
and 81% had at least one AL dose-pack in stock [7], while 
in this study 90% had diagnostic services and 91% had at 
least one formulation of AL available. The majority of HWs 
were adherent to the national malaria treatment guidelines 
when testing for malaria, evidenced by the 76% of suspect 
uncomplicated malaria patients who were tested for malaria 
when tests were available. This proportion is similar to that 
reported in Kenya when both microscopy and RDT were 
available at HFs [15] but higher than that reported in many 
other malaria high-transmission settings since release of the 
WHO recommendation for universal access to malaria diag-
nostic testing [16–22]. Most testing was done using RDTs, 
likely because they were more widely available on the day of 
the survey, and microscopy is limited to higher-level facilities 
in Malawi. The widespread use of RDTs reflects their accept-
ability and consistent supply as a malaria diagnostic tool 
since they were introduced in Malawi in 2011.
HWs were more likely to test for malaria when patients 
spontaneously reported fever, vomiting or headache, 
and were less likely to test when patients reported a skin 
problem. A similar association between patient-reported 
symptoms of fever and skin problem on malaria treat-
ment has been reported in Uganda [19]; in Vanuatu, 
patients with a main complaint of fever were more likely 
to get tested for malaria [20].
Similar to other studies in Malawi, Central African 
Republic and Zambia, neither supervision nor guide-
lines alone were associated with HW practices [23–25]. 
In this study, analyses identified an interaction between 
HW supervision in the previous 6 months and access to 
the latest national malaria treatment guidelines. Unlike 
most interactions, this did not reflect synergy between 
these two factors but rather that association between 
guidelines and testing varied by whether or not the HW 
received supervision. It is difficult to explain this find-
ing with information in this study, as HWs with neither 
Table 5 Artemisinin combination therapy (artemether-lumefantrine or artesunate-amodiaquine) dispensing, dosing 
and patient knowledge for uncomplicated malaria patients
a 1 confirmed malaria patient had both AL and ASAQ dispensed; AL was the only ACT dispensed to presumed malaria patients
b ASAQ dosing information was coded as correct for patients who received the correct strength or number of ASAQ tablets and for those with missing dosing 
information
c 1 patient (a 5 years old child weighing 14 kg) received lower than recommended strength formulation for ASAQ
d Only pertains to patients who were dispensed AL. Patients with ASAQ were not asked this question
e Aspects of AL dosing were evaluated when the drug was dispensed and included patient knowledge of correct: number of AL tablets to take at each dose, number 
of AL doses to take per day and number of days to complete the AL dose. Aspects of correct ASAQ dosing included patient knowledge of correct number of ASAQ 
tablets to each for each dose and the total number of days to complete the entire ASAQ dose
n/N Weighted percent (95% CI)
1. ACT dispensing and dosing
Total number of uncomplicated (confirmed and presumed) malaria patients 725/2342 33.0 (27.2, 38.8)
 Received an ACT (AL or ASAQ)a 609/725 84.9 (77.2, 92.5)
  ACT dispensed 534/609 88.9 (80.1, 97.7)
  ACT correctly dosed when dispensedb 505/534 94.9 (92.7, 97.2)
Type of ACT dispensed
 AL dispensed 517/534 97.2 (93.3, 100.0)
  AL correctly dosed when dispensed 490/534 92.5 (88.2, 96.8)
 ASAQ dispensed 17/534 2.8 (0.0, 6.7)
  ASAQ correctly dosed when dispensedc 16/17 93.6 (3.7, 100.0)
HWs provided patients with the following ACT counselling information
 First dose of ACT given at HF 72/534 16.8 (3.2, 30.3)
 HW explained how to take ACT at home 495/534 91.8 (88.7, 94.8)
 HW advised what to do in case of vomiting within 30 min of taking ACT 36/534 7.5 (4.8, 10.1)
HW instructed to complete all doses of ACT even if he/she feels better 316/534 60.9 (52.7, 69.1)
 HW instructed to take AL with food, milk or milk containing drinkd 141/517 27.9 (20.2, 35.7)
2. Patient ACT dosing knowledge
Correct knowledge regarding all aspects of ACT dosinge 404/534 78.1 (72.3, 83.8)
Knows correct amount of ACT (tablet or syrup) to take per dose 460/534 85.9 (81.3, 90.6)
Knows total number of days to complete ACT dose 473/534 90.6 (86.8, 94.3)
Knows correct number of AL doses to take per day 474/534 89.5 (86.0, 93.0)
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supervision nor guidelines may possess characteris-
tics that were not measured. A further assessment of 
these HWs may be needed to support them better, but 
immediate priority should be given to ensuring that 
these HWs have at least regular supervision and copies 
of guidelines.
Table 6 Factors associated with appropriate testing among suspect uncomplicated malaria patients (N = 1427)
Ref means referent group
Interaction term included in the model. Other factors with p value ≥0.1 in the univariate analysis that were not included in the multivariable model were: (1) Patient-
level factors: patient spontaneous report to the HW of malaria, chills, fatigue, joint pain, weakness or cough; (2) HW-level factors: HW age, number of patients seen by 
the HW, number of years of formal training received, number of years of clinical experience, latest training on malaria case management, access to the latest malaria 
treatment guidelines and supervision in the last 6 months; (3) HF-level factors: MoH vs CHAM operated HFs, availability of thermometers, number of patients at the HF 





Unadjusted OR (95% 
CI)
p value Adjusted OR (95% 
CI)
p value
Patient spontaneously reported these complaints to the HW
 Fever
  Yes 950 784 (81.8) 2.6 (1.6–4.3) <0.0001 2.6 (1.7–4.0) <0.0001
  No 477 288 (62.9) Ref Ref
 Headache
  Yes 481 380 (79.4) 1.4 (0.9–1.9) 0.055 1.5 (1.1–2.2) 0.017
  No 946 692 (73.8) Ref Ref
 Vomiting
  Yes 223 194 (86.1) 2.2 (1.2–4.2) 0.016 2.0 (1.0–4.0) 0.040
  No 1204 878 (73.8) Ref Ref
 Skin problem
  Yes 80 37 (49.0) 0.3 (0.2–0.5) <0.0001 0.4 (0.2–0.6) 0.0001
  No 1347 1035 (77.1) Ref Ref
n/N Weighted percent (95% CI) OR (95% CI) p value
Interaction term included in the model: supervision * 2013 malaria treatment guidelines available
 Supervision * Guidelines 299/389 75.9 (66.1, 85.8) 2.2 (0.8, 6.6) 0.143
 Supervision * No guidelines 438/559 78.8 (69.5, 88.0) 2.7 (0.9, 8.0) 0.073
 No supervision * Guidelines 161/190 87.4 (77.6, 97.2) 6.2 (1.6, 24.7) 0.009
 No supervision * No guidelines 174/289 56.8 (36.2, 77.4) Ref
Table 7 Factors associated with appropriate treatment among presumed uncomplicated malaria patientsa (N = 178)
Data from facilities unable to test patients at the time of the survey
a Only statistically significant factors with p < 0.05 in the multivariable analysis have odds ratio estimates shown in the table above. Other factors included in the 
logistic regression model were: patient age in years, patient spontaneous complaint of cough and headache (which was a confounder). Other factors with p value 
≥0.1 in the univariate analysis that were not included in the multivariable model were: (1) Patient-level factors: patient spontaneous report of malaria, vomiting, chills, 
fatigue, joint pain, skin problem, weakness or cough to the HW; (2) HW-level factors: Number of patients seen by the HW, number of years of formal training received, 
number of years of clinical experience, latest training on malaria case management, and access to the latest malaria treatment guidelines; (3) HF-level factors: MoH vs 
CHAM operated HFs, availability of thermometers, number of patients at the HF and the number of HWs at the HF




p value Adjusted OR (95% 
CI)
p value
Patient spontaneously reported fever to the HW
 Yes 126 79 (68.6) 3.5 (1.7–7.3) 0.001 5.7 (1.9–17.6) 0.002
 No 52 19 (38.4) Ref Ref
Patient temperature (°C)—surveyor measured 1.3 (1.0–1.7) 0.032 1.5 (1.1–1.9) 0.005
HW age (years) 1.0 (1.0–1.1) 0.001 1.1 (1.0–1.1) <0.0001
Number of supervision visits 1.1 (0.9–1.3) 0.135 1.2 (1.0–1.4) 0.029
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The vast majority of patients were seen at facilities (91%) 
with malaria diagnostics available on the day of the survey. 
When these patients tested positive for malaria, nearly all 
(93%) received correct treatment for malaria. In contrast, 
when testing was not available and patients were presumed 
to have malaria, treatment was sub-optimal, with only 60% 
of presumed malaria patients receiving a recommended 
treatment. This suggests that HWs make better malaria 
treatment decisions based on diagnostic test results. Fur-
thermore, when HWs treated patients for malaria, they 
followed guidelines in selecting the recommended first- 
or second-line anti-malarial most of the time. In addi-
tion, HWs generally accepted negative test results: only 
3% of test-negative (either RDT or microscopy) patients 
received an anti-malarial. This is much lower than the 31% 
treatment rate reported in 2011 for microscopy-negative 
patients [8] and substantially lower than treatment rates 
for test-negative patients in studies from Kenya, Tanzania, 
Uganda, and Burkina Faso [15, 26–28].
Pre-referral treatment for suspect severe malaria was 
extremely poor. The majority of patients were not given 
IM artesunate or quinine despite the fact that HWs docu-
mented a sign or symptom of severe malaria for over half 
of them. This is especially concerning since most HWs 
in the study recently received malaria case management 
refresher training that focused on treatment of severe 
malaria. Interestingly, half (53%) of suspect severe malaria 
patients were given an oral ACT, which may reflect a lack 
of awareness of severe malaria symptoms or a percep-
tion of treatment guidelines as a proposition rather than 
a recommendation requiring strict adherence. It is also 
concerning that 35% of suspect severe malaria patients 
did not get any anti-malarial, as mortality from untreated 
severe malaria approaches 100% [29]. Pre-referral treat-
ment for suspect severe malaria is critical for patients 
of all ages; adults  >50  years have been reported to have 
a higher risk of death from severe malaria compared to 
children  <10 years [30]. Encouragingly, a recent study 
found that when patients are admitted to hospitals with a 
diagnosis of severe malaria they had high rates of correct 
treatment at 93% [31]. However, a better understanding of 
why HWs rarely follow guidelines for managing severely 
ill patients at the outpatient level is needed.
Furthermore, when HWs did not have access to 
diagnostic testing, the odds of appropriate treatment 
increased nearly six-fold for patients who spontane-
ously reported history of fever to the HW. This finding 
was similar in Kenya [32]. Despite all patients with sus-
pect malaria presenting with fever or history of fever, 
fever was spontaneously reported to HWs by only two-
thirds of suspect uncomplicated malaria patients and 
only half of those who did not report fever had the HW 
ask about it. This highlights an opportunity for targeting 
malaria-related public health interventions at the patient-
HW interaction, encouraging patients to report fever to 
HWs and reminding HWs to ask about fever. Unlike other 
studies which have found that lower-level HWs tend to 
adhere to guidelines better than higher-level cadres [19, 
20, 32], an association between HW cadre and malaria 
testing or treatment was not identified in this study.
Vomiting is a common malaria symptom, therefore having 
patients understand that they should take another dose in 
case of vomiting within half-an-hour is important in treating 
malaria appropriately. Only 8% of patients were advised what 
to do in case of vomiting within 30 min of taking the ACT. 
In addition, only 17% of uncomplicated malaria patients who 
received the drug were given the first dose at the HF. This is 
a missed opportunity to promote adherence to dispensed 
medications. Patients have been reported to be more likely 
to complete all the prescribed doses if they are given the 
first dose at the HF [33]. Furthermore, opportunities exist in 
instructing patients to take AL with food and to complete all 
doses of the ACT even when patients feel better. This study 
did not explore why HWs miss these important counsel-
ling messages when dispensing ACT. With most HFs having 
access to clean drinking water and cups for administering 
oral medications on the day of the survey, it was expected 
that a higher proportion of patients would have taken the 
first dose at the HF. Perhaps HWs are not fully aware of the 
importance of directly observing patients taking the first 
dose and perhaps assume that patients will intuitively know 
to return to the HF for more ACT doses in case of vomiting 
within half-an-hour of taking the medication or the work-
load does not allow enough room for counseling. A thorough 
qualitative study to understand what drives health workers to 
provide counseling services may be needed to better under-
stand this. Despite HWs not fully providing all necessary 
drug counselling messages, most patients expressed good 
understanding of the correct dosing regimen prescribed.
Limitations
This study has several limitations. Survey teams did not 
directly observe patient-HW interactions and relied on 
patient report, which is subject to recall bias. However, 
over 95% of patients had their clinical encounter recorded 
in the health booklet, which was examined by the survey 
teams. The study was limited to seven districts in south-
ern Malawi that had received malaria case management 
refresher training in 2014. The results of this study can-
not be generalized to the entire nation of Malawi or to 
districts where HWs had not received the same malaria 
refresher training. However, HFs in this region are typical 
of other HFs across Malawi. It is therefore expected that 
the malaria case-management practices in this region are 
similar to those for the rest of the country, and previous 
studies have found no significant regional difference in 
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malaria treatment practices [7]. The presence of survey 
teams at HFs likely influenced HW practices even though 
they did not directly observe their work. This may have 
overestimated appropriate treatment since HWs may 
have been more likely to follow guidelines under assumed 
observation. Furthermore, the multivariable analysis 
for appropriate treatment was limited to 178 presumed 
malaria patients seen at ten HFs, a small sample size that 
may have underpowered the analysis.
Finally, the accuracy and validity of RDT results was 
not evaluated to make sure that HWs followed manu-
facturer instructions and that the kits were in good 
condition.
Conclusions
Malawi has shown tremendous progress in malaria case 
management since the ‘test-and-treat’ policy was imple-
mented in HFs by the MoH. Most HFs have diagnostic 
test availability, and management of patients who test 
positive (confirmed malaria) or negative (not malaria) 
was excellent at 93 and 96%, respectively. However, there 
is much room for improving management of malaria, 
especially when testing is not available and when patient 
symptoms are severe. Targeting public health interven-
tions at the patient-HW interaction to encourage patients 
to report history of fever to the HW and remind HWs 
to ask about fever or measure temperature is critical to 
improving both malaria testing and treatment practices 
in southern Malawi. In addition, the NMCP could pro-
vide extra supervision visits to HWs, offer more sup-
port to younger HWs, and eliminate RDT stock-outs 
by strengthening supply chain management. Finally, 
immediate attention should be given to improving HW 
recognition and pre-referral treatment of suspect severe 
malaria, which was vastly undertreated in this study.
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